Navigation Links
Independent Pharmacy Cooperative to Distribute Promescent, Topical Medication for Premature Ejaculation
Date:6/14/2013

HUNTINGTON BEACH, Calif., June 14, 2013 /PRNewswire/ -- The Independent Pharmacy Cooperative (IPC) and Absorption Pharmaceuticals (AP) have signed a distribution agreement whereby IPC will make AP's topical treatment for premature ejaculation, Promescent, available to its 4,500+ member pharmacies throughout the United States.

Promescent is fast becoming first-line therapy for premature ejaculation by numerous urologists and Large Urology Groups Practice Association (LUGPA) members across the U.S., replacing off-label medications which have known side effects. Promescent is available over-the-counter by way of FDA monograph 21 CFR 348.10 and has minimal risk of systemic side effects. The effectiveness, ease-of-use, safety, and low cost per dose of the medication are key reasons for its rise in popularity among physicians.

"Urologists want their patients to have convenient and private locations for obtaining Promescent after their office visit," says Jeff Abraham, CEO of Absorption Pharmaceuticals. "The relationship with IPC now gives patients in virtually every location in the country the fast and confidential access to what has become a mainstream medication for PE."

Many independent pharmacies provide compounding services such as Trimix for erectile dysfunction.  Some urologists who prescribe Trimix and other injection therapies for ED are recommending Promescent to these patients in order to achieve a better overall sexual experience.

"We have witnessed a steady growth in product demand since our first member pharmacy started  carrying Promescent," says Dean Slaugenhoup, director of contracts and purchasing at IPC . "Our mission at IPC is to provide our members cost-effective and convenient access to products that have passed a threshold of acceptance by physicians and Promescent is now clearly in this category. It was time to formalize the relationship."

IPC is now stocking Promescent at its two distribution centers and making members aware of the Promescent's availability.

About Absorption Pharmaceuticals

Absorption Pharmaceuticals, based in Huntington Beach, California, is the maker of Promescent, the world's first FDA-approved topical treatment for premature ejaculation.  Promescent is now first-line PE therapy for numerous urologists and sexual medicine experts throughout the United States and Canada.  Visit www.promescent.com.

About Independent Pharmacy Cooperative (IPC)

Over the past 30 years, IPC has evolved into the nation's largest group purchasing organization for independent pharmacies. IPC represents over 4500 pharmacy members. Located in Sun Prairie, WI and staffed by 75 employees, IPC prides itself on providing the most progressive and effective programs and services to put profit back in the independent pharmacy.

Contact: Greg Kaminski, +1-412-741-1430, greg.kaminski@promescent.com


'/>"/>
SOURCE Absorption Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Intarcia Supports American Diabetes Association Call For Independent Review Of Incretin-Based Therapies
2. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
3. Managed Health Care Associates, Inc. (MHA) Released Results of Sixth Annual Independent Long Term Care Member Study with Expanded Specialty Pharmacy Findings
4. Agnitio Launches Rainmaker One to Remove the Complexity of Managing Independent Apps
5. Independent Drugstore Lobby Wants Sweeping Antitrust Exemptions to Charge Higher Prescription Drug Prices
6. Independent Study Published in Clinical Infectious Diseases Highlights the Importance of Antimicrobial Removal Systems in Blood Culture to Rapidly and Accurately Aid in the Diagnosis of Sepsis
7. China Botanic Appoints Jack Zhao as Independent Director
8. PQ Bypass Graduates from the Fogarty Institute for Innovation, Establishes Independent Operations
9. H. D. Smith Supports Local Hospitals, Nursing Homes, Clinics And Independent Retail Pharmacies Throughout Hurricane Sandy
10. Registry Data Shows 90% Of Patients Independent, Free Of Significant Disabilities After Treatment With Codman System For Wide-necked Aneurysms
11. 3SBio Independent Committee Selects Legal Counsel in connection with Going Private Proposal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... BASEL, Switzerland and SAN DIEGO ... Houston , Inc., a global leader in viral gene ... gene therapy treatments for congestive heart failure and other ... to develop a scalable manufacturing process and produce cGMP-grade ... clinical trials. --> ...
(Date:2/10/2016)... Immune Pharmaceuticals Inc. (NASDAQ: IMNP ), ... has filed a patent application directed to the treatment ... --> --> The new invention ... (histamine dihydrochloride) in combination with immune checkpoint inhibitors. The ... of Ceplene and IL-2 therapy in patients with Acute ...
(Date:2/10/2016)... ANGELES , Feb. 10, 2016  Oxis International ... cancer drug, OXS-1550, was described as a "clinical trial ... the drug went into complete cancer remission. ... University of Minnesota Masonic Cancer Center. --> ... University of Minnesota Masonic Cancer Center. --> ...
Breaking Medicine Technology:
(Date:2/10/2016)... IN (PRWEB) , ... February 10, 2016 , ... ... benefits advisory organization, welcomes S.S. Nesbitt as the latest addition to its growing ... has seven other locations throughout the Southeast, from Orlando to Huntsville and in ...
(Date:2/10/2016)... ... ... Armune BioScience signed a definitive agreement with ARCpoint Labs ... the country. Launched in April of 2015, Apifiny is the only cancer specific, non-PSA ... volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized Apifiny ...
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact ... , Pioneering book "Better with Age: The Ultimate Guide to Brain Training" by award-winning ... improve memory. The book’s publication date is March 16, 2016. A free review ...
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has joined the award-winning ... to physicians. The integration will enable Allscripts users to post open appointments to ... mobile app. , The partnership gives Everseat substantial added power to help Allscripts ...
(Date:2/10/2016)... ... ... Workrite Ergonomics this week announced the launch of the Conform Monitor Arm Series, ... was to develop a product from the ground up that would provide the most ... Hulsey, Product Manager for Workrite Ergonomics. “The Conform series features a wide variety ...
Breaking Medicine News(10 mins):